Overview Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy Status: Terminated Trial end date: 2013-12-01 Target enrollment: Participant gender: Summary The current study will investigate whether the addition of Neuradiab to surgery, radiation and adjuvant chemotherapy (temozolomide) will improve the survival of patients with glioblastoma and whether the drug regimen is safe. Phase: Phase 3 Details Lead Sponsor: Bradmer Pharmaceuticals Inc.Treatments: AntibodiesDacarbazineImmunoconjugatesTemozolomide